Xenon Pharmaceuticals Inc. insider trading
Every open-market purchase and sale by Xenon Pharmaceuticals Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Xenon Pharmaceuticals Inc.’s insiders pay?
From September 24, 2015 to October 1, 2026, 21 insiders reported 22 open-market purchases and 31 sales not made under a pre-set plan in Xenon Pharmaceuticals Inc. Twelve months after each purchase was reported, the shares were +9.2% against the S&P 500 on average (median +46.6%), over 3 purchases with a full year of prices; 67% beat the index. After sales, the shares moved −10.7% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on June 29, 2016 into $8,680 by November 2, 2026, −1.4% a year. It held shares 21% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $12,711 (+2.4% a year), and held throughout $43,080 (+15.2%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Pimstone Simon N. | CEO | 1 | — | — | 7 | +3.6% (7) | June 1, 2023 |
| Holler Frank A | Director | 0 | — | — | 6 | −29.4% (6) | June 1, 2021 |
| Patou Gary | Director | 2 | — | — | 3 | −18.3% (3) | November 22, 2024 |
| Mortimer Ian | PRESIDENT & CEO | 3 | −66.3% (1) | 0% | 1 | −24.4% (1) | October 1, 2026 |
| Robin Sherrington | EVP, Strategy & Innovation | 0 | — | — | 4 | +5.4% (4) | March 8, 2024 |
| Azab Mohammad | Director | 3 | — | — | 0 | — | November 16, 2017 |
| Empfield James R. | EVP, Drug Discovery | 1 | — | — | 2 | +7.8% (2) | August 16, 2022 |
| Gannon Steven | Director | 1 | — | — | 2 | −29.9% (1) | August 13, 2026 |
| Aulin Sherry | Chief Financial Officer | 0 | — | — | 2 | −9.0% (2) | December 19, 2024 |
| Bvf Partners L P/il | 10% owner | 2 | — | — | 0 | — | June 19, 2017 |
| Kenney Christopher John | Chief Medical Officer | 1 | +46.6% (1) | 100% | 1 | −9.0% (1) | March 24, 2023 |
| Svoronos Dawn | Director | 1 | — | — | 1 | −21.9% (1) | August 24, 2023 |
| Biotechnology Value Fund II LP | 10% owner | 1 | — | — | 0 | — | August 16, 2017 |
| Bvf Partners Os Ltd. | 10% owner | 1 | — | — | 0 | — | June 29, 2017 |
| Garofalo Elizabeth A. | Director | 0 | — | — | 1 | −30.5% (1) | March 11, 2024 |
| Goldberg Y. Paul | VP of Clinical Development | 0 | — | — | 1 | −17.4% (1) | September 24, 2015 |
| Hayden Michael R | Director | 1 | — | — | 0 | — | August 14, 2017 |
| Kelly Thomas Patrick | Chief Financial Officer | 1 | — | — | 0 | — | October 1, 2026 |
| Lampert Mark N | 10% owner | 1 | — | — | 0 | — | June 23, 2017 |
| Scheller Richard H | Director | 1 | — | — | 0 | — | August 14, 2017 |
| Von Seggern Christopher | Chief Commercial Officer | 1 | +47.4% (1) | 100% | 0 | — | December 7, 2021 |
When several insiders traded Xenon Pharmaceuticals Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Xenon Pharmaceuticals Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged +26.7% against the index. After 4 selling crowds, −4.6%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 28, 2024 | 3 selling | −13.8% | −20.2% | −37.4% |
| May 31, 2023 | 3 selling | −7.4% | −22.0% | −29.2% |
| September 30, 2022 | 4 selling | +1.7% | −14.4% | −26.9% |
| March 31, 2022 | 3 selling | +15.9% | +38.3% | +27.5% |
| January 31, 2022 | 2 buying | +14.7% | +26.7% | +51.7% |